AVDL vs. BCYC, COLL, BDSI, IMUX, OVID, BBIO, RARE, IMVT, OGN, and APLS
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Bicycle Therapeutics (BCYC), Collegium Pharmaceutical (COLL), BioDelivery Sciences International (BDSI), Immunic (IMUX), Ovid Therapeutics (OVID), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Immunovant (IMVT), Organon & Co. (OGN), and Apellis Pharmaceuticals (APLS). These companies are all part of the "medical" sector.
Avadel Pharmaceuticals vs.
Avadel Pharmaceuticals (NASDAQ:AVDL) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, community ranking, valuation and profitability.
Avadel Pharmaceuticals has higher earnings, but lower revenue than Bicycle Therapeutics. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.
Avadel Pharmaceuticals currently has a consensus price target of $24.43, indicating a potential upside of 109.51%. Bicycle Therapeutics has a consensus price target of $40.13, indicating a potential upside of 95.35%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Avadel Pharmaceuticals is more favorable than Bicycle Therapeutics.
69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 4.8% of Avadel Pharmaceuticals shares are owned by insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Avadel Pharmaceuticals has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
Avadel Pharmaceuticals received 208 more outperform votes than Bicycle Therapeutics when rated by MarketBeat users. However, 70.16% of users gave Bicycle Therapeutics an outperform vote while only 66.02% of users gave Avadel Pharmaceuticals an outperform vote.
Avadel Pharmaceuticals has a net margin of -52.53% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Avadel Pharmaceuticals' return on equity.
In the previous week, Avadel Pharmaceuticals had 3 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 11 mentions for Avadel Pharmaceuticals and 8 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.32 beat Avadel Pharmaceuticals' score of -0.15 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.
Summary
Avadel Pharmaceuticals beats Bicycle Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AVDL) was last updated on 11/23/2024 by MarketBeat.com Staff
Free AVDL Stock Alerts